| P50 | author | Frank Struyf | Q55186651 |
| P2093 | author name string | Murdo Ferguson | |
| | Tino F Schwarz | |
| | Ulrich Behre | |
| | Marc Dionne | |
| | Florence Thomas | |
| | Pemmaraju Suryakiran | |
| | Peter Hillemanns | |
| | Barbara Romanowski | |
| | Klaus Peters | |
| | Brian Ramjattan | |
| | Linda M Ferguson | |
| | Karin Schulze | |
| P2860 | cites work | Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women | Q28251260 |
| | Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years | Q28255234 |
| | Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme | Q30780649 |
| | Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial | Q34342056 |
| | Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial | Q34580726 |
| | Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach | Q34631422 |
| | Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine | Q35268615 |
| | Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years | Q35577825 |
| | Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years | Q35918834 |
| | Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years | Q35918838 |
| | Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study | Q35918842 |
| | Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. | Q36584350 |
| | Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women | Q36796538 |
| | Prophylactic HPV vaccines: new interventions for cancer control | Q37241351 |
| | Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications | Q40025709 |
| | Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study | Q42245617 |
| | Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial | Q42257816 |
| | Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose | Q42280340 |
| | Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years | Q43452461 |
| | Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer | Q43596600 |
| | Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial | Q44350321 |
| | Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens inCervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine | Q45372298 |
| | Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant | Q45403548 |
| | Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial | Q45552005 |
| | Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women | Q46313199 |
| | Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. | Q47951363 |
| | Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial | Q49169372 |
| | Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States | Q49206271 |
| | Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc | Q51865830 |
| | Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007–2008 | Q64129516 |
| | Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines | Q82251822 |
| | Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine | Q82883166 |
| | Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up | Q83428460 |
| P433 | issue | 5 | |
| P304 | page(s) | 1155-1165 | |
| P577 | publication date | 2014-02-27 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study | |
| P478 | volume | 10 | |